Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on PURETECH HEALTH PLC. We currently have 12 research reports from 1 professional analysts.
|24Mar17 07:00||RNS||PureTech Announces Novartis Licensing Agreement|
|14Mar17 07:00||RNS||Notice of Results|
|22Dec16 07:00||RNS||Director/PDMR Shareholding|
|20Dec16 16:53||RNS||Research Update: Two Studies from Tal Medical|
|15Dec16 07:00||RNS||Research Update: PureTech's Karuna data positive|
|19Oct16 07:00||RNS||PureTech's Vedanta Granted European Patent|
|03Oct16 12:07||RNS||Second Price Monitoring Extn|
Frequency of research reports
Research reports on
PURETECH HEALTH PLC
PURETECH HEALTH PLC
N+1 Singer - PureTech - Drug development agreement with Novartis
24 Mar 17
The licensing and equity agreement with Novartis is an exciting development for PureTech, and in line with Novartis’ strategy of drug development collaboration with specialist biopharmaceutical companies. We look forward to the upcoming publication of data from Novartis’ initial Phase IIa trials, and to more detail on the intended future development of the two programmes, with anticipation.
N+1 Singer - PureTech - PureTech re-allocating cash after disappointing data from Tal Medical
21 Dec 16
Tal Medical’s dose optimisation study in treatment-resistant major depressive disorder failed to meet its primary endpoint and follows the disappointing data in June from its RAPID trial. PureTech is now assessing where to re-allocate the capital it had earmarked for Tal Medical. PureTech owns 54.2% of Tal Medical and it represented c.10% of PureTech’s valuation of its growth stage companies at the end of 2015 (Tal Medical has now been moved to project phase). We believe Tal Medical’s valuation may be written down, although note there have been some positive developments with other companies within PureTech’s portfolio which continues to offer a diversified approach and reduced risk exposure. We continue to view Vedanta as the most interesting PureTech operating company and look forward to it commencing its first clinical trial in 2017.
N+1 Singer - PureTech - Mixed Karuna proof-of-concept data
15 Dec 16
Karuna’s proof of concept trial of its KarXT product reduced the incidence of adverse events but not the severity. KarXT continues to be safe. The group intends to undertake a Phase II trial in 2017. PureTech owns 79.6% of Karuna on a diluted basis and is also eligible to potential product royalties. Karuna represented around 12% of PureTech’s valuation of its growth stage companies at 31 December 2015. We continue to view Vedanta as the most interesting PureTech operating company and look forward to it commencing its first clinical trial in 2017. We continue to expect additional portfolio company data over the coming year. We remain at Buy.
N+1 Singer - PureTech - Interim results highlight upcoming newsflow
07 Sep 16
PureTech’s interim results highlight a busy six months with multiple portfolio financings and development progression with 20 clinical trials ongoing. We continue to expect five proof-of-concept readouts as well as multiple pivotal or registration trial readouts, along with a potential product launch (Akili) over the next 24 months. PureTech is well financed with a consolidated cash balance of $297.4m at the period end. PureTech is trading at an EV/portfolio value of 0.7x, an undeserved discount to the sector in our view. We remain at Buy with a 243p Target Price.
N+1 Singer - Morning Song 07-09-2016
07 Sep 16
Consort Medical (CSRT LN) In line AGM statement & contract with AZ | Futura Medical (FUM LN) Stellar data from pivotal MED2002 (Eroxon™) trial | Karolinska Development AB (KDEV SS) Forecast update post Q2: portfolio value credible, but stock expensive | N Brown Group (BWNG LN) Deep value but more downgrades after tricky Q2 | OMG (OMG LN) Yotta continues international expansion with Amey contract | Oxford Pharmascience Group (OXP LN) Interim results provide update on development activities | PureTech (PRTC LN) Interim results highlight upcoming newsflow | Servelec Group (SERV LN) Interims reflect difficult H1. Outlook more positive | Vectura Group (VEC LN) Solid AGM update
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
28 Mar 17
ClearStar* (CLSU): Building a background for growth (CORP) | Sound Energy (SOU): TE-8 results (HOLD) | LiDCO* (LID): 2017 should be a transformative year (CORP) | Proteome Sciences* (PRM): FY 2016 in line. Moving towards breakeven (CORP) | Fulcrum (FCRM): Significant market potential, rising margins and a strong balance sheet (BUY) | Mortgage Advice Bureau (MAB1): Strong and growing intellectual property (BUY) | 7digital* (7DIG): Open offer result (CORP)
Small Cap Breakfast
28 Mar 17
Path Investments—Publication of prospectus from the Energy Investment Company. Raising £1.4m. Admission due on or around 30 March | Franchise Brands—Schedule 1 detailing £28m reverse takeover of Metro Rod. Admission expected 11 April | Alpha FX Group— Schedule 1 from the foreign exchange provider focused on managing exchange rate risk for UK corporates that trade internationally. Fundraise TBC. Admission expected 7 April. | K3 | Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. | Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Tufton | Oceanic Assets– Offer extended to 9 May to enable investors to complete further due diligence.